Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For type 1 diabetes mellitus. Sold as Basaglar, Semglee. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Insulin Glargine (sold as Basaglar, Semglee), first approved Dec 16, 2015, with 0 new uses approved and 0 published complete response letters.
First approved: Dec 16, 2015
Applications: 2
New uses approved: 0
Complete response letters: 0
First approved in the EU: Jun 9, 2000
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
INSULIN GLARGINE-YFGN U100 PEN: $2.90 per MLGeneric · -51% in a year
INSULIN GLARGINE-YFGN U100 VL: $6.09 per MLGeneric · 0% in a year
BASAGLAR 100 UNIT/ML KWIKPEN: $20.92 per MLBrand · 0% in a year
SEMGLEE (YFGN) 100 UNIT/ML PEN: $25.74 per MLBrand · 0% in a year
SEMGLEE (YFGN) 100 UNIT/ML VL: $26.07 per MLBrand · +1% in a year
Lantus XR, new approvalA drug in a new dosage form indicated for the treatment of diabetes mellitus in cases where insulin therapy is indicated. · Sanofi K.K. · Jul 3, 2015
Clinical Trials
26 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Mylan Pharms Inc